Ignite Creation Date:
2025-12-25 @ 2:07 AM
Ignite Modification Date:
2025-12-31 @ 11:10 AM
Study NCT ID:
NCT04421560
Status:
RECRUITING
Last Update Posted:
2025-09-03
First Post:
2020-06-04
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Pembrolizumab, Ibrutinib and Rituximab in PCNSL
Sponsor:
Dana-Farber Cancer Institute
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-08-01
Start Date Type:
ACTUAL
Primary Completion Date:
2025-12-05
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-01-05
Completion Date Type:
ESTIMATED
First Submit Date:
2020-06-04
First Submit QC Date:
None
Study First Post Date:
2020-06-09
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-08-29
Last Update Post Date:
2025-09-03
Last Update Post Date Type:
ESTIMATED